Scientists Make Progress in Developing Ebola Vaccine

The vaccine which is a collaboration between scientists from various institutions appeared to be highly protective against a lethal Ebola virus infection in mice

While the focus of the entire world is on developing a vaccine for the deadly COVID-19, scientists are relentlessly researching on other diseases such as the Marburg and Ebola viruses, that could potentially set off a pandemics as well.

Nikolai Petrovsky, Professor at Flinders University says that it is a risk to not focus on other threats in the midst of the current pandemic. He cautioned that the equally potent Ebola virus could evolve into a more lethal form.

"While a live virus vaccine has recently been developed to protect against Ebola, it is not necessarily effective against all forms of Ebola and Marburg and is sensitive to heat which requires it to be stored frozen - a problem in poor tropical countries in Africa with erratic power supplies, which is where Ebola resides," said Petrovsky.

Highly Protective Against Ebola Virus

In the latest collaboration with US partners, a vaccine turbocharger called Advax™ adjuvant, developed at Professor Petrovsky's Australian laboratory was combined with a synthetic protein against Ebola developed by the United States Army Medical Research Institute of Infectious Disease (USAMRIID).

COVID-19 vaccine trial (Representational picture)

The resulting vaccine appeared to be highly protective against a lethal Ebola virus infection in mice, including after just a single injection. As well, the protection generated by the vaccine was long-lasting and shown to be able to be transferred to naïve mice using antibodies taken from the immunized mice.

This work provides promise that a more convenient and heat-stable version of the Ebola vaccine can be developed, which could then play a key role in preventing further Ebola outbreaks in Africa, Professor Petrovsky says.

"While developing a COVID-19 vaccine is a top priority including for our team, we must also continue developing vaccines against a wide range of other potentially catastrophic pandemic diseases including Ebola and Marburg viruses, as these continue to periodically jump from wild animals to people in Africa," he says.

Need Improve The World's Vaccine Pipeline

The Petrovsky lab and Vaxine Pty Ltd is currently using the same Advax™ vaccine turbocharger approach to develop a recombinant protein vaccine against COVID-19, which is now in late-stage animal testing ahead of human trials in Australia.

"Like coronaviruses, we must continue research into improving the world's vaccine pipeline for diseases, particularly rapidly changing viral infections believed to be transmitted to people from wild animals," he says. The World Health Organisation notes Ebola virus disease (EVD) is a severe, generally fatal illness with an average case fatality of over 50 percent.

The 2014-2016 outbreak in West Africa was the largest and most complex Ebola outbreak with more cases and deaths than all others combined since the virus was discovered in 1976. It also spread between countries, starting in Guinea then moving across land borders to Sierra Leone and Liberia. Infected patients travelled to many countries around the globe before the outbreak was stopped by quarantine measures.

(With inputs from agencies)

This article was first published on May 18, 2020